GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » COGS-to-Revenue

Kadimastem (XTAE:KDST) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Kadimastem COGS-to-Revenue?

Kadimastem's Cost of Goods Sold for the six months ended in Dec. 2023 was ₪0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was ₪0.00 Mil.

Kadimastem's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kadimastem's Gross Margin % for the six months ended in Dec. 2023 was N/A%.


Kadimastem COGS-to-Revenue Historical Data

The historical data trend for Kadimastem's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem COGS-to-Revenue Chart

Kadimastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kadimastem Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kadimastem COGS-to-Revenue Calculation

Kadimastem's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Kadimastem's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kadimastem  (XTAE:KDST) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kadimastem's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Kadimastem COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kadimastem's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kadimastem (XTAE:KDST) Business Description

Traded in Other Exchanges
Address
Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR
Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem (XTAE:KDST) Headlines

No Headlines